Advertisement

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Jul
15
Today In Oncology
Gedatolisib Combinations Approved by FDA for HR-Positive/HER2-Negative Breast Cancer
FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion–Positive Solid Tumors
American Cancer Society Reports Latest Global Cancer Statistics
Setmelanotide in Patients With Acquired Hypothalamic Obesity From Brain Tumors
Previously Untreated Advanced NSCLC With High PD-L1 Expressionb PD-1/-L1 Inhibitor Monotherapy or Chemoimmunotherapy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo